|
|
Blood, 15 March 2005, Vol. 105, No. 6, pp. 2601-2607.
Prepublished online as a Blood First Edition Paper on November 16, 2004; DOI 10.1182/blood-2004-08-3205.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life
Riccardo Saccardi,
Gian Luigi Mancardi,
Alessandra Solari,
Alberto Bosi,
Paolo Bruzzi,
Paolo Di Bartolomeo,
Amedea Donelli,
Massimo Filippi,
Angelo Guerrasio,
Francesca Gualandi,
Giorgio La Nasa,
Alessandra Murialdo,
Francesca Pagliai,
Federico Papineschi,
Barbara Scappini, and
Alberto M. Marmont, for the Italian GITMO-Neuro Intergroup
From the Bone Marrow Transplantation Unit, Careggi Hospital, University of Florence, Italy; the Department of Neurological Sciences, Ophthalmology and Genetics, Centre of Excellence for Biomedical Research, University of Genoa, Italy; the Istituto Nazionale Neurologico "Carlo Besta," Milan, Italy; the Unit of Clinical Epidemiology and Trials, National Cancer Institute, Genova, Italy; the Bone Marrow Transplantation Unit, S. Spirito Hospital, Pescara, Italy; the Department of Oncology and Hematology, Policlinico of Modena, Italy; the Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute, S. Raffaele Hospital, Milan, Italy; the Internal Medicine and Hematology Department, S. Luigi Hospital, Orbassano, Italy; the Bone Marrow Transplantation Unit, S. Martino Hospital, Genova, Italy; the Bone Marrow Transplantation Unit, Binaghi Hospital, Cagliari, Italy; and the Department of Haematology, S. Chiara Hospital, Pisa, Italy.
Hematopoietic stem cell transplantation (HSCT) has been proposed for the treatment of severe multiple sclerosis (MS). In a phase 2 multicenter study we selected 19 non–primary progressive MS patients showing high disease activity on the basis of both brain magnetic resonance imaging (MRI) and sustained clinical deterioration despite conventional treatments. After stem cell mobilization with cyclophosphamide (CY) and filgrastim, patients were conditioned with BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea), cytosine arabinoside, etoposide, and melphalan (BEAM) followed by antithymocyte globulin (ATG). Unmanipulated peripheral blood stem cells (PBSCs) were then infused. No maintenance treatment was administered with a median follow-up of 36 months (range, 12 to 72 months). All patients showed clinical stabilization or improvement; 3 subsequently deteriorated, 1 beyond the baseline. No MRI active lesions were detected after the HSCT except in 1 patient who showed a new lesion at 4.5 years. Infections were limited and restricted to 3 months after HSCT. Health-related quality of life was assessed through the 54-item MS quality of life (MSQOL-54) questionnaire, showing a statistically significant improvement in both composite scores and in most of the individual domains. HSCT is able to induce a prolonged clinical stabilization in severe progressive MS patients, resulting in both sustained treatment-free periods and quality of life improvement.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J Fagius, J Lundgren, and G Oberg
Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation
Multiple Sclerosis,
February 1, 2009;
15(2):
229 - 237.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J Larghero, D Farge, A Braccini, S Lecourt, A Scherberich, E Fois, F Verrecchia, T Daikeler, E Gluckman, A Tyndall, et al.
Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis
Ann Rheum Dis,
April 1, 2008;
67(4):
443 - 449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Gladstone, K. W. Zamkoff, L. Krupp, R. Peyster, P. Sibony, C. Christodoulou, E. Locher, and P. K. Coyle
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Arch Neurol,
October 1, 2006;
63(10):
1388 - 1393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Daumer, L M Griffith, W Meister, R A Nash, and J S Wolinsky
Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation
Multiple Sclerosis,
April 1, 2006;
12(2):
174 - 179.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. L. Mancardi, A. Murialdo, P. Rossi, F. Gualandi, G. Martino, A. Marmont, F. Ciceri, A. Schenone, R. C. Parodi, E. Capello, et al.
Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis
Multiple Sclerosis,
June 1, 2005;
11(3):
367 - 371.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. K. Burt, B. Cohen, J. Rose, F. Petersen, Y. Oyama, D. Stefoski, G. Katsamakis, E. Carrier, T. Kozak, P. A. Muraro, et al.
Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Arch Neurol,
June 1, 2005;
62(6):
860 - 864.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Muraro, D. C. Douek, A. Packer, K. Chung, F. J. Guenaga, R. Cassiani-Ingoni, C. Campbell, S. Memon, J. W. Nagle, F. T. Hakim, et al.
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients
J. Exp. Med.,
March 7, 2005;
201(5):
805 - 816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
